The NEAT Predictive Model for Survival in Patients with Advanced Cancer.
- Author:
Amanda ZUCKER
1
;
Chiaojung Jillian TSAI
;
John LOSCALZO
;
Pedro CALVES
;
Johnny KAO
Author Information
- Publication Type:Original Article
- Keywords: Life expectancy; Radiation oncology; Prognosis
- MeSH: Calibration; Discrimination (Psychology); Drug Therapy; Hospitalization; Humans; Life Expectancy; Liver; Neoplasm Metastasis; Prognosis; Prospective Studies; Radiation Oncology
- From:Cancer Research and Treatment 2018;50(4):1433-1443
- CountryRepublic of Korea
- Language:English
- Abstract: PURPOSE: We previously developed a model to more accurately predict life expectancy for stage IV cancer patients referred to radiation oncology. The goals of this study are to validate this model and to compare competing published models. MATERIALS AND METHODS: From May 2012 to March 2015, 280 consecutive patientswith stage IV cancerwere prospectively evaluated by a single radiation oncologist. Patients were separated into training, validation and combined sets. TheNEAT model evaluated number of active tumors (“N”), Eastern Cooperative Oncology Group performance status (“E”), albumin (“A”) and primary tumor site (“T”). The Odette Cancer Center model validated performance status, bone only metastases and primary tumor site. The Harvard TEACHH model investigated primary tumor type, performance status, age, prior chemotherapy courses, liver metastases, and hospitalization within 3 months. Cox multivariable analyses and logisticalregressionwere utilized to compare model performance. RESULTS: Number of active tumors, performance status, albumin, primary tumor site, prior hospitalizationwithin the last 3 months, and liver metastases predicted overall survival on uinvariate and multivariable analysis (p < 0.05 for all). The NEAT model separated patients into four prognostic groups with median survivals of 24.9, 14.8, 4.0, and 1.2 months, respectively (p < 0.001). The NEAT model had a C-index of 0.76 with a Nagelkerke’s R2 of 0.54 suggesting good discrimination, calibration and total performance compared to competing prognostic models. CONCLUSION: The NEAT model warrants further investigation as a clinically useful approach to predict survival in patients with stage IV cancer.
